ProfileGDS5678 / 1425528_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 86% 88% 85% 90% 82% 85% 88% 89% 89% 83% 88% 86% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.4911586
GSM967853U87-EV human glioblastoma xenograft - Control 26.5920786
GSM967854U87-EV human glioblastoma xenograft - Control 36.8324988
GSM967855U87-EV human glioblastoma xenograft - Control 46.5949485
GSM967856U87-EV human glioblastoma xenograft - Control 57.1964890
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.6966482
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.2146385
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.7900788
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.0430989
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.0156689
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.0882983
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.8530588
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.4423386
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0309983